Anti-Spike-RBD-hlgG1-HRP

Monoclonal human IgG1 antibody against SARS-CoV and SARS-CoV-2 Spike (clone CR3022)

conjugated to HRP

Catalog code: srbd-mab1-hrp

https://www.invivogen.com/sars2-spike-cr3022-mab-isotypes

For research use only, not for diagnostic or therapeutic use

Version 20K30-NJ

PRODUCT INFORMATION

Contents:

+ 100 μg of Anti-Spike-RBD-hIgG1-HRP, provided azide-free and lyophilized

Target: SARS-CoV & SARS-CoV-2 Spike receptor binding domain (RBD) Tag: HRP (horseradish peroxidase) in N-terminal

Source: CHO cells

Isotype: Human IgG1

Light chain type: Kappa

Clonality: Monoclonal

Purification: By affinity chromatography with protein G

Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Storage

- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for at least 1 year.

- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

Quality control

- The antibody isotype has been confirmed by ELISA.

- Anti-Spike-RBD-hlgG1-HRP has been functionally validated by ELISA using a coated SARS-CoV-2 Spike-RBD-His fusion peptide.

- Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue[™] TLR2 and TLR4 cellular assays.


PRODUCT DESCRIPTION

Anti-Spike-RBD-hIgG1-HRP is a recombinant monoclonal antibody (mAb) originally described under the name of CR3022, a SARS-CoV neutralizing antibody¹. It is conjugated to HRP in N-terminal to allow direct ELISA readout using the HRP substrate. Anti-Spike-RBDhIgG1-HRP features a variable region that cross-reacts with the receptor binding domain (RBD) of the Spike protein of SARS-CoV and SARS-CoV-2, and the constant region of the human IgG1 (hIgG1) isotype. Anti-Spike-RBD-hIgG1-HRP was generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G.

CR3022 scientific background

Spike RBD is a privileged candidate for vaccination and treatment strategies in the context of COVID-19. The anti-Spike RBD clone CR3022 is a SARS-CoV neutralizing antibody that was obtained from the screening of an antibody-phage library and converted to a human IgG1 format¹. Modeling and *in vitro* studies have shown that CR3022 is also binding to SARS-CoV-2 RBD². This cross-reactivity is explained by the 86% shared amino acid identity between the CR3022 epitopes from the two viruses².

TECHNICAL SUPPORT InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong: +852 3622-3480 E-mail: info@invivogen.com



Simplified schematic of CR3022- and ACE2-binding sites in SARS-CoV and SARS-CoV-2 Spike RBD

However the neutralization potency of CR3022 for SARS-CoV-2 is still unclear^{3,4}. Importantly, CR3022 does not interfere with the ACE2 binding motif¹⁻³. Thus, CR3022 could be used alone or in combination with other antibodies or soluble ACE2 to maximize the neutralization of SARS-CoV-2 (Wuhan-Hu-1, D614) and mutant isolates⁵.

lgG1 lsotype effector function

Human IgG1 binds with high affinity to the Fc receptor on phagocytic cells. It displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (see reverse side).

ter Meulen J. et al., 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLos Med. 3(7):e237. 2. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV-2 bydestruction of the prefusion Spike.bioRxiv. DOI:10.1101/2020.05.05.079202.
Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections, 9(1):382-385. 5. Korber B. et al., 2020. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv. DOI:10.1101/2020.04.29.069054.

METHODS

Anti-Spike-RBD-hlgG1-HRP resuspension (200 µg/ml)

<u>Note:</u> Ensure you see the lyophilized pellet before resuspension.

- Add 500 μl of sterile water to the vial and gently pipette until completely resuspended.

- Prepare aliquots and store at 4°C or -20°C until required.



ANTIBODY ISOTYPE COLLECTION

For your research, InvivoGen provides an Anti-Spike-RBD isotype family. This collection consists of mAbs comprising the variable region of the CR3022 clone, and differing constant regions of both native and engineered human or murine isotypes. The isotypes differ in their functional and effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC), as presented in the table below. The Anti-Spike-RBD isotype family will assist you in studying the various effector functions of the different isotypes, and help you determine which isotype is the most suited for your application.

Effector functions of native and engineered human isotypes

Effector	Native			Engineered
functions	lgG1	lgM	lgA1	lgG1NQ
ADCC	++	+	+	-
ADCP	+++	-	+	-
CDC	++	+++	-	+/-

Effector functions of native and engineered murine isotypes

Effector	Native	Engineered	
functions	lgG2a	lgG1e3	
ADCC	++	-	
ADCP	+++	-	
CDC	++	-	

RELATED PRODUCTS

Product	Catalog Code
Anti-Spike-RBD-hlgG1 Anti-Spike-RBD-hlgG1NQ Anti-Spike-RBD-hlgM Anti-Spike-RBD-hlgA1 Anti-Spike-RBD-mlgG2a Anti-Spike-RBD-mlgG1e3 Anti-CoV2RBD-c1-hlgG1 Anti-CoV2RBD-c2-hlgG1	srbd-mab1 srbd-mab12 srbd-mab5 srbd-mab6 srbd-mab10 srbd-mab15 cov2rbdc1-mab1 cov2rbdc2-mab1

Note: For human or murine isotype controls, please visit our website https://www.invivogen.com/antibodies

Spike-RBD-Fc Spike-RBD-His

fc-sars2-rbd his-sars2-rbd

Note: For more products related to COVID-19 research, please visit our website <u>https://www.invivogen.com/covid-19</u>

